[Source: PR-USA] – Ascalon International Inc., a newly established oncology drug developer, today announced an agreement for an exclusive option to license CerRx Inc’s intravenous (IV) fenretinide (4-HPR) product.
Ascalon will continue its ongoing collaboration with CerRx but will assume full responsibility for development and commercialization for IV fenretinide. CerRx will receive developmental milestone payments and a share of certain sublicensee income and royalties. Additional terms of the deal were not disclosed.
For more information: New Oncology Developer Ascalon International Inc. Announces Deal With CerRx Inc